Atlas Bio raises $10m seed round for simulated clinical trials
Creandum led the new financing as Atlas Bio disclosed $12.5m in total funding across seed and an earlier pre-seed round.
New seed capital
Atlas Bio has raised $10 million in seed financing led by Creandum. The company also disclosed an earlier $2.5 million pre-seed round co-led by First Momentum Ventures and LEA Partners, bringing total funding to $12.5 million.
The Swiss company plans to expand its scientific and commercial teams, deepen validation of its platform and onboard more enterprise customers.
Comparing development paths
Atlas Bio uses AI models trained on human biological data to simulate how patient groups may respond to treatments. The platform helps biopharma teams compare mechanisms, indications and patient cohorts before making development decisions.
Founded in 2024 by Simon Romanski and Sebastian Bayer, the Basel company combines machine learning with pharmaceutical development expertise.
Use of funds
Expand scientific and commercial teams
Validate the platform and onboard enterprise customers